UBI集團訊息
United BioPharma invited to present UB-421 Phase II clinical trial results in late breaker session at CROI 2017
The late breaker session in CROI aims to convey and share the latest breakthrough research resulst to experts from academia, the pharmaceutical industry, and clinical and anti-epidemic fields.
The results of the UB-421 Phase II Clinical Trial confirms the role of UB-421 monotherapy as a potential substitution treatment for HAART therapy. Over a 16-week treatment period, UB-421 reached a 100% primary endpoint to inhibit HIV vira; rebound and potentially restore the T cell immunity of HIV patients, showing superior efficacy in HIV/AIDS monoclonal antibody drug treatments.
About United BioPharma (6471)
United BioPharma (UBP) was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnered with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs to improve the health of mankind.
About UB-421
UB-421 is a humanized monoclonal antibody, which recognizes and binds to domain 1 of the CD4 molecule, the same site for HIV virus binding. This direct competition for binding to CD4 is termed competitive inhibition and effectively blocks the entry of HIV virus into CD4+ cells, thus inhibiting HIV infection. Competitive inhibition also prevents generation of drug resistance resulting from the mutation of the HIV virus.
UB-421 is an innovative antibody drug developed solely by United BioPharma (UBP). UBP has received Technology Development grants from the Taiwan government five times, won the Silver Prize in 2012 and Gold Prize in 2014 of the Pharmaceutical R&D Award. UBP also won the Gold Prize of the Taipei Biotech Award for its innovative R&D, and was selected as a Flagship Project and a Cross-Strait Pilot Program of Pharmaceutical Collaborative Development by the Taiwan FDA. UBP’s achievement in R&D and UB-421’s potential to treat AIDS have been repeatedly recognized.
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.